HER-2

ERBB2

A gene on chromosome 17q11.2-q12 that encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. ERBB2 has no ligand-binding domain and thus cannot bind growth factors; it does, however, bind to other ligand-bound EGF receptor family members, forming a heterodimer, stabilising ligand binding and enhancing kinase-mediated activation of downstream signalling pathways (e.g., those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase).

Molecular pathology
ERBB2 amplification and overexpression commonly occurs in breast and ovarian cancers.

HER-2

c-erbB-2, HER-2/neu Oncology An erbB family oncogene related to epidermal growth factor; HER-2 overexpression, espceically breast CA, and stomach CAs, which have a ↓ survival and ↓ time to relapse. See Breast cancer.
References in periodicals archive ?
Also, with a large HER-2 negative patient population that is not eligible for treatment with Herceptin, there is a strong unmet need and opportunity for therapies that are effective in these patients, including those who overexpress HER-2," Trewartha concludes.
Clearance was given for Invitrogen's SPOT-Light test to count copies of the so-called HER-2 gene in tumor tissue that regulates the growth of cancer cells, the FDA said.
In validating the new method, we also developed a multiplex, single-tube methodology, using aQRT-PCR, to detect HER-2 copy number variations in microdissected breast cancer samples; in formalin-fixed, paraffin-embedded (FFPE) specimens; and in plasma circulating DNA.
Research suggests that the drug halves the chances of the aggressive HER-2 form of breast cancer returning.
Abbott Laboratories, Abbott Park, IL, has received FDA approval for its Vysis PathVysion HER-2 DNA Probe Kit to detect the HER-2/neu gene in breast cancer patients for use in identifying women with metastatic breast cancer who could benefit from Herceptin therapy.
com adds HER-2 Positive Breast Cancer Market in the US 2015-2019 and Global HER-2 Positive Breast Cancer Market 2015-2019 industry research reports in its store.
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab (Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) breast cancer, and a separate study investigating neratinib safety and efficacy when given with paclitaxel (Taxol(R), Bristol-Myers Squibb) in patients with HER-2 dependent solid tumors.
Both studies were made up of women whose disease is fueled by the HER-2 protein and whose tumors had continued to grow even after initial treatment with Herceptin, also known as trastuzumab.
Amplification was considered to be present when more than 4 green fluorescence signals were identified in each nucleus and amplified tumors had a minimum of 20 nuclei with more than 4 copies of the HER-2 gene.
Downers Grove, IL) says the data supports the notion that FISH is the most accurate means of assessing HER-2 status in breast cancer patients.
0 million in grants from the DOD in the development of its live Listeria vaccines directed against HER-2 for breast cancer and HMW-MAA, an antiangiogenic vaccine.